Member Info for Bobbler

Curious to see how the Womble’s will put a negative spin on this RNS.

The Board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the Company's negotiating position as it continues to engage in discussions with potential licence partners."

Bridges, Brilliant got me chuckling, despite BBC News trying its hardest to beat me down with all the Negativity. Keep the humour going :-)

Wimbledon common must be empty.....

Completely agree. Every post on every coy is negative. Think he/she is a "sippy cup", quarter full type of person.

Worth a Read even! Red wines flowing :-)

https://www.biospace.com/article/top-2020-biopharma-m-and-a-deals/

Happy New Year to one and all.
Thanks to all those who take the time to share theit knowledge and experience.

Statement on the WHO solidarity website:

“Treatment options under study
New treatment options will be added to the Solidarity Trial in the future.

The original treatment options under study were hydroxychloroquine, remdesivir, lopinavir/ritonavir and interferon beta-1a.They were found to have little or no effect on overall mortality, initiation of ventilation and duration of hospital stay in hospitalized patients.”

Here’s hoping Sareum will soon feature on the list.

Not counting chickens, but I’m definitely counting Chk1’’ins and there adding up nicely :-)

Workinginpharma - Suggest looking at Soller in NW Majorca, beautiful mountain / beach combo, scrote free. Was due to get married there in October. Every cloud..... :-)

Thoth2. If it is a GSK/Sar deal, any thoughts on what
the share price might reach?

Your definitely not alone. Thankfully there are a number of poster who really do know their stuff. Been here initially since 2010/11. Got caught on a couple of spikes but always viewed it as a long term investment. I keep 4m in an ISA and have a trading pot of 500k shares. Have been able to average down over the last 12 months so currently at circa .8p
Even at these prices its provided a great return if i sold up. However pretty confident there is a long way to go yet. GLA

BoilB....... I don't think you should be investing in this type of shares if you don't understand the science. Its really very simple. Let me explain.....the TYk2 does the ticky thing and the JAK1's.......well they do the Jaky thing. Hope that's clarified it. :-)
Seriously, I've tried my hardest to understand it and I think i,m reasonably bright but its beyond my pay-scale.

Not sure if posted previously, but good read ref Tyk2

https://theconversation.com/discovery-of-gene-associated-with-20-autoimmune-diseases-leads-to-promising-drug-trials-131957

It would appear Caution should be observed when administering Tocilizumab to patients with a low platelet count. Which is not ideal as evidence suggests this is a common problem with severe Covid infections.

Nice - The British National Formulary pharmaceutical reference book: TOCILIZUMAB cautions.... “low platelet count“ .

British Journal of Haematology study: Thrombocytopenia (low platelet count) was more prevalent in patients with severe COVID-19.

Num4. Great post, I think you are correct. The IP really is the key.

https://www.bbc.co.uk/news/health-54949799

“We will also need to continue seeking effective therapies for those with Covid-19, even when a vaccine is available.”

https://amp.theguardian.com/commentisfree/2020/nov/10/hurdles-covid-19-vaccine-science-solutions-pandemic

Totally agreed Andy. Nothing changed other than the potential news ref vaccine. This in itself isn’t exactly a surprise, everyone knew there are a number of vaccines in the p3 stage. Crazy drop and now all the doom and gloom.